Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $21.29.

Several equities research analysts recently issued reports on the stock. Morgan Stanley decreased their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. Barclays reduced their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. The Goldman Sachs Group reduced their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Arcus Biosciences in a report on Wednesday, May 7th. Finally, Wells Fargo & Company reduced their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th.

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Gilead Sciences Inc. bought a new position in Arcus Biosciences in the 4th quarter worth approximately $447,610,000. Woodline Partners LP boosted its stake in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after purchasing an additional 1,603,367 shares during the period. Boxer Capital Management LLC bought a new position in Arcus Biosciences in the 4th quarter worth approximately $23,857,000. Vanguard Group Inc. boosted its stake in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the period. Finally, RA Capital Management L.P. bought a new position in Arcus Biosciences in the 1st quarter worth approximately $8,920,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $9.44 on Friday. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $18.98. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $8.95 and a two-hundred day simple moving average of $10.03. The stock has a market capitalization of $999.81 million, a price-to-earnings ratio of -2.25 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million during the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. Arcus Biosciences’s quarterly revenue was down 80.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. Analysts forecast that Arcus Biosciences will post -3.15 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.